Cardio Diagnostics Holdings Inc. Warrant
CDIOWStock
$0.02
Market Cap—
P/E—
Div yield—
Beta1.35
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-26.40%
Price vs S&P 500 (4W)16.33%
VGM Score21.15
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CDIOWCardio Diagnostics Holdings Inc. Warrant | — | — | D | $0.02 |
| IDXXIdexx Laboratories Inc | D | B | C | $576.07 |
| LNTHLantheus Holdings, Inc | C | B | B | $105.11 |
| CLDXCelldex Therapeutics, Inc | F | F | B | $35.40 |
| NEOGNeogen Corp | C | C | B | $10.33 |
| NTLAIntellia Therapeutics, Inc | D | C | C | $11.86 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | F | $9.60 |
| QDELQuidelOrtho Corporation Common Stock | C | C | C | $18.24 |
| ACHVAchieve Life Sciences, Inc. | F | F | A | $5.96 |
| MYGNMyriad Genetics Inc | C | C | B | $6.19 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $5.32 |
About
Cardio Diagnostics Holdings develops AI-powered epigenetic blood tests for detecting and assessing coronary heart disease risk. The company's product suite includes Epi+Gen CHD for symptomatic risk assessment, PrecisionCHD for CHD detection, and Actionable Clinical Intelligence, a platform that delivers personalized patient insights by analyzing epigenetic and genetic biomarkers. These solutions aim to improve cardiovascular disease management and patient outcomes through advanced diagnostic capabilities.